Melissa K Hallow (Karen M Hallow, K Melissa Hallow)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 13

Top Topics

Ejection Fraction

Diabetic Nephropathy

Transcatheter Aortic Valve Replacement

Top Venues

Journal of clinical pharmacology

American journal of physiology. Renal physiology

Diabetes, obesity & metabolism

PLoS computational biology

This page only lists publications with an associated author ORCID identifier.

Publications

Hongtao Yu, Peter J Greasley, Hiddo J Lambers Heerspink, Philip Ambery, Christine Ahlstrom, Bengt Hamren, Anis A Khan, David W Boulton, Melissa K Hallow
The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial. British journal of pharmacology (2024)
Sanchita Basu, Hongtao Yu, Jonathan R Murrow, Melissa K Hallow
Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling. PLoS computational biology 19 (11) (2023)
Erfan Maddah, Melissa K Hallow
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone. Journal of pharmacokinetics and pharmacodynamics 49 (4) (2022)
Hongtao Yu, Sanchita Basu, Weifeng Tang, Robert C Penland, Peter J Greasley, Jan Oscarsson, David W Boulton, Melissa K Hallow
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology (2021)
Hongtao Yu, Sanchita Basu, Melissa K Hallow
Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis. PLoS computational biology 16 (8) (2020)
Melissa K Hallow, David W Boulton, Robert C Penland, Gabriel Helmlinger, Emily H Nieves, Daniël H van Raalte, Hiddo L Heerspink, Peter J Greasley
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. The Journal of pharmacology and experimental therapeutics 375 (1) (2020)
Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, Melissa K Hallow
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology 61 (5) (2020)
Melissa K Hallow, Peter J Greasley, Gabriel Helmlinger, Lulu Chu, Hiddo J Heerspink, David W Boulton
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. American journal of physiology. Renal physiology 315 (5) (2018)
Hiddo J Lambers Heerspink, C David Sjöström, Silvio E Inzucchi, Melissa K Hallow, Valerie A Cain, Peter Rossing, Bergur V Stefansson, Peter Sartipy
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes, obesity & metabolism 21 (3) (2018)
Melissa K Hallow, Yeshitila Gebremichael, Gabriel Helmlinger, Volker Vallon
Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. American journal of physiology. Renal physiology 312 (5) (2017)
Melissa K Hallow, Gabriel Helmlinger, Peter J Greasley, John Joseph Valentine McMurray, David W Boulton
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, obesity & metabolism 20 (3) (2017)
Jessica A Brady, Melissa K Hallow
Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin. Journal of clinical pharmacology 58 (3) (2017)
Charles H Van Brackle, Ryan A Harris, Melissa K Hallow
Exposure-response modeling of flow-mediated dilation provides an unbiased and informative measure of endothelial function. Journal of applied physiology (Bethesda, Md. : 1985) 122 (5) (2016)